Anti-FAP monoclonal antibody F19-I-131
Alternative Names: Anti-fibroblast activation protein monoclonal antibody F19; F19 monoclonal antibody I-131Latest Information Update: 15 Aug 2007
At a glance
- Originator Boehringer Ingelheim; Ludwig Institute for Cancer Research; Memorial Sloan-Kettering Cancer Center
- Class Monoclonal antibodies
- Mechanism of Action Fibroblast activation protein antagonists; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 16 Oct 2003 No development reported - Phase-I for Solid tumours in Australia (Infusion)
- 16 Oct 2003 No development reported - Phase-I for Solid tumours in Germany (Infusion)
- 16 Oct 2003 No development reported - Phase-I for Solid tumours in USA (Infusion)